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patient networks to gather qualitative data on patient-reported out-
come (PRO) concepts relevant to chronic lymphocytic leukemia (CLL).
Methods: Between August and November 2013, US-residing members
of the PatientsLikeMe online CLL patient community completed open-
ended web-based surveys designed to elicit descriptions of CLL
symptoms, impacts, and treatment-related perceptions. Qualitative
telephone follow-up interviews were conducted with a subsample of
respondents. Survey responses and interview transcripts were coded
for qualitative analysis using Atlas.ti. Results: Fifty survey responses
were included in the analyses. Participants were age 60.5  6.9 years,
54% female, and 96% white. When surveyed, 20% were receiving
current treatment, 16% were in remission, and 64% were treatment-
naïve. Among respondents, 369 descriptions of CLL symptoms were
coded. Fatigue-related symptoms were expressed most frequently,
with 54% reporting “fatigue,” “tiredness,” or both in their responses.
These concepts were followed by night sweats (38%), swollen lymph
nodes (32%), and frequent infections (28%). Among impacts of CLL,ee front matter & 2016 Published by Elsevier Inc.
(ISPOR). This is an open access article under the
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ndence to: Kelly P. McCarrier, Health Research Assoworry and fear (66% of respondents), depressed feelings (52%), and
work limitations (50%) were noted most frequently. Conclusions:
Survey results identiﬁed constitutional symptoms of CLL included in
existing PRO instruments and the literature. Although the ﬁndings
suggest that qualitative data obtained through social media applica-
tions can be potentially useful in supporting concept identiﬁcation for
newly developed PRO instruments, they also indicate that online
approaches alone may not be sufﬁcient to achieve efﬁcient and
exhaustive concept elicitation. Further research is needed to identify
whether the results can support content validity in the same way as
established qualitative research methods.
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media, content validity.
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Recent developments have illustrated the great potential for use
of online applications to facilitate interactions within patient
communities and between patients and care providers [1]. Out-
side the health care setting, social media such as Facebook or
Twitter have demonstrated advantages over traditional media in
disseminating and collecting information directly from individu-
als, and comprise one of the fastest growing digital technologies
in the world [2,3]. Patients with long-term conditions are increas-
ingly searching and gathering online stakeholders to ﬁnd infor-
mation to quantify their disease progression and better manage
their conditions [4].
Within the ﬁeld of medical outcomes research, patient-
powered research networks (PPRNs) are being evaluated as a
potentially less burdensome source of biomedical data and may,
thus, have a role in emerging methods for qualitative data
collection [5,6]. Such communities vary in their strengths assources of new data and in their potential to be validated against
traditional medical data sources, as well as in terms of data
quality, level of structure, and ability to support longitudinal data
collection [7].
Recognizing the power of direct interaction among patients,
companies such as PatientsLikeMe (PLM), and others have devel-
oped platforms that enable individuals to take an active role in
managing their health by connecting to share experiences, give
and receive support from one another, and compare treatment
options, disease symptoms, and experiences with people who
have similar health conditions [8–11]. This PPRN enables patients
to connect and communicate using shared language and experi-
ences that may not be apparent in a clinical encounter [12].
The features of the existing PLM platform and associated patient
communities provide a fertile setting in which to explore
potential alternative approaches to qualitative data collection to
support the development of patient-reported outcome (PRO)
instruments.on behalf of International Society for Pharmacoeconomics and
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priate sample of patients is referred to as a best practice
“essential for establishing the content validity of a PRO instru-
ment” [13]. Individual interviews and focus group discussions are
the most frequently used qualitative data collection methods for
this type of concept elicitation (CE) process. Despite their beneﬁts
in terms of the depth of qualitative content, one perceived
drawback of these approaches is the labor-intensive nature of
qualitative data collection via interview methods [6]. This has led
PRO developers to examine alternative methods of ascertaining
information directly from patients about the disease-related
concepts that are relevant and important to their experiences.
Harnessing the potential of PPRNs as a forum for a CE process is
one such approach, but its full beneﬁts and challenges have yet to
be thoroughly explored by PRO developers [6,14,15].
Among the expected challenges of online clinical research, the
reliance on self-reported clinical data, particularly with regard to
diagnostic and other clinical characteristics, is an acknowledged
limitation of online social network–based approaches to PRO-
related CE efforts [6]. When contrasted with the clinician-based
patient screening and recruitment approaches typically
employed with in-person concept elicitation, the use of self-
reported data in online data collection potentially limits the
degree to which researchers can accurately describe study sam-
ples. Although researchers have developed strategies to attain
clinical conﬁrmation of key clinical information gathered directly
from patients via self-report, the willingness of patients to
authorize such access to their medical information is currently
unknown and thus warrants investigation.
Essential to understanding the full promise of these new
approaches will be empirical tests of speciﬁc CEmethods leveraging
PPRNs. Although there have been recent examples of PRO develop-
ment undertaken using online tools and PPRN-based approaches
[16,17], we believe our study to be among the ﬁrst to speciﬁcally
examine this particular combination of qualitative methods in a
way that allows comparisons to the sets of concepts elicited
through previous condition-speciﬁc PRO development efforts.
In this paper, we describe the process and results of admin-
istering an online CE questionnaire coupled with telephone
follow-up interviews to participating members of an established
digital patient community for the purpose of identifying
condition-speciﬁc symptoms, impact, and treatment-related con-
cepts expressed as relevant and important to patients with
chronic lymphocytic leukemia (CLL).
By conducting data collection in this way, we sought to evaluate
whether there is reasonable proof-of-concept for the feasibility of
this PPRN approach as a tool for qualitative concept elicitation.
Speciﬁcally, we intended to examine four research questions: How does the set of identiﬁed symptom and impact concepts
resulting from this CE process compare with those known in
the literature and assessed in existing PRO instruments
developed to measure the CLL experience? Is there evidence of saturation of concept for the data
collected through open-ended PPRN questionnaire responses? Are additional concepts identiﬁable through qualitative
follow-up interviews to supplement PPRN questionnaire data? What are study participants’ attitudes toward providing
researchers with access to their medical record information
to conﬁrm details of the clinical diagnosis of CLL and supple-
ment patient-reported data from a PPRN?Selection of CLL as a Case Study
Patients with CLL were considered a valuable test case for
examining the usefulness of a PPRN to collect patient data forseveral reasons. First, since CLL is not a highly prevalent disease
[18–20], collecting patient data from CLL patients online would
illustrate the extent to which digital communities can be useful
in recruiting relatively uncommon conditions and rare diseases.
Second, the PLM platform is optimized for use by patients with
chronic health conditions, as it allows patients to track symp-
toms, treatments, and side effects over time [8,9]. CLL, unlike
tumor-based cancers, tends to resemble a chronic disease, in
which patients must manage their condition and treatments over
time [21,22]. Last, CLL provides an optimal case study to evaluate
this novel CE approach because several disease-speciﬁc PRO
instruments have already been developed for use in CLL [23,24].
The literature supporting these existing instruments provides
evidence of the CLL-speciﬁc concepts identiﬁed via prior patient
research, against which the ﬁndings of this study can be
compared.
PRO instruments such as the FACT-Leu [23] and the EORTC
Quality of Life Module for Chronic Lymphocytic Leukaemia [24]
were designed with patient input speciﬁcally for use in CLL and
have similar content. The importance of the concepts captured in
these instruments is further supported by other instruments
such as the Life Ingredient Proﬁle for hematologic malignancies,
which includes extensive physician input [25]. As such, compar-
ing the breadth of patient-expressed concepts elicited in the
current study with the collection of CLL-speciﬁc concepts known
to prior researchers facilitates assessment of the feasibility of the
PPRN approach for effective concept elicitation.Methods
This mixed methods study employed a nonprobability conven-
ience sample of adults with CLL to participate in a web-based
survey and telephone interview, through which both quantitative
(via closed-ended survey items) and qualitative (via open-ended
survey items and verbal responses to the semistructured inter-
view questions) data were collected. Eligibility criteria were
designed to facilitate a sample of patients with CLL, which would
be broadly reﬂective of the variations in patient, disease, and
treatment characteristics present in target populations for CLL
clinical trials in the United States. Subjects were eligible for
inclusion in the study if they: 1) were 18 years of age or above,
2) were residents of the United States, 3) were members of the
PLM CLL community, and 4) self-reported a diagnosis of CLL on
the online questionnaire.
Prior to study data collection, the study protocol was reviewed
and approved by Quorum Review IRB (Seattle, WA), and all
participants provided informed consent. During registration with
the system, all PLM users provided consent to be invited to
participate in research. Following IRB approval of the study
protocol, potentially eligible participants were identiﬁed by PLM
from the CLL member pool. Beginning August 15, 2013, qualiﬁed
patients were sent an initial contact message via PLM’s internal
private messaging system and invited to participate in the study.
Those who did not respond to the message within 10 days of the
initial invitation were sent a reminder message.
In addition to these approaches to existing PLM members,
IRB-approved recruitment advertisements were placed on the
Google and Facebook webpages. Additional invitations to new
PLM members with CLL were sent every 4 to 6 days while the
recruitment advertisements brought new members to the site.
All interested patients who responded to their invitations
were asked to complete the online consent form via the internal
PLM survey system, and once they consented, they were asked to
complete the web-based study questionnaire (described below).
Participants who completed the survey were compensated with a
$45 Amazon gift card.
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The web-based study questionnaire was composed of three main
parts: the descriptive variables (Part A), the open-ended CE
questionnaire (Part B), and a patient attitude questionnaire about
hypothetical approaches to share medical record information
with researchers (Part C).
Part A was designed to collect demographic and clinical
characteristics of the respondent, including date of birth, gender,
marital status, race/ethnicity, education level (in years), employ-
ment status, type of health insurance, and current health status.
They were also asked to provide other descriptive variables about
their CLL, including date of diagnosis, stage of disease, treatment
status, and type of treatment received. Descriptive variables
facilitated subgroup analyses based on disease and treatment
status. Part B was an exploratory questionnaire aimed at eliciting
patient experience of symptoms, impacts on general quality of
life, and perceptions about treatment. This section included
open-ended survey items based on the type of questioning often
used in standard qualitative CE interviews [13] and contained a
modiﬁed day-reconstruction exercise [26] to elicit descriptions of
CLL symptoms and life impacts. Example questions included: Could you describe the events leading up to your initial
diagnosis? What symptoms do you remember talking to your doctor
about when you were ﬁrst diagnosed? What would you say your worst symptom is now? How would
you describe what this symptom feels like to someone who
does not have it? Could you describe the areas of your life you feel have been
the most affected by having CLL? Could you describe any activities that you have had to cut
back (or stop) because of your CLL?
Part C assessed patient preferences and attitudes about two
hypothetical approaches researchers might employ to conﬁrm
diagnostic and clinical information about CLL. Speciﬁcally, par-
ticipants were asked to rate the likelihood of their 1) consenting
to have their doctor release information about their CLL directly
to the research team, or 2) collecting the information from their
doctor and then providing it to the research team.Follow-Up CE Interviews
Anticipating the possibility of sparse data collection without
active probing of patient responses, supplemental qualitative
patient interviews were conducted via telephone on a sample
of 20 patients who reported at least one symptom. The telephone
interviews focused on further understanding the symptoms and
effects of CLL in light of the patient’s previous responses to
questionnaire items, and on probed further about their experi-
ence with their condition, including their thoughts about the
future and feelings about future treatment. These telephone
interviews were audio-recorded and transcribed for coding and
qualitative analysis to identify relevant concepts and any infor-
mation missed during the initial online data collection. All
interviewers were trained ﬁeld staff at Health Research Associ-
ates (HRA) and had experience with interviewing patients for the
purposes of PRO measure development. During the telephone
interview process, subjects were given a brief introduction to the
interview process, a reminder regarding the purpose of the
interview, and reassurance about the conﬁdential nature of the
interview. All patient interviews were conducted over the phone
by trained HRA interviewers and lasted approximately 20 to 30
minutes.Pilot Test and Participant Recruitment
Prior to the initiation of data collection, the survey was ﬁelded for
10 days and yielded 20 subjects consenting to the survey. Of the
consenting subjects, 9 completed a portion of the survey, and 11
completed the full survey. Additionally, 9 of the 11 completing
the survey agreed to also participate in the telephone follow-up
interview.
Data from the questionnaires completed during this initial
pilot wave were collectively reviewed by the study interviewers
and used to inform and optimize the content of the interview
discussion guide prior to the launch of the full data collection
effort. Following this pilot test, the full data collection effort was
launched in August 2013 and lasted for approximately 14 weeks
until the sampling target of 50 completed questionnaires was
reached.Data Management and Study Analyses
Web-based survey data, including participants’ numeric
responses to categorical items and verbatim responses to open-
ended items were exported from tabular Excel ﬁles for analysis.
Statistical Package for the Social Sciences (SPSS) (Version 18) was
used for descriptive analyses of categorical survey response
variables, and the verbatim responses to open-ended variables
were exported to individual text documents for content analysis.
The digital audio recordings of the telephone interview
sessions were transcribed by a professional transcription com-
pany and returned to HRA as text ﬁles. For content analysis of
this qualitative CE data, transcript documents and open-ended
survey response text were loaded into ATLAS.ti (Version 7.0)
software program [27].
The primary goal of transcript coding was to organize and
catalog respondents’ descriptions of the key symptom, impact,
and treatment-related concepts reported during the CE exercise.
In order to organize the subject expressions, a preliminary coding
framework was developed using the detailed study objectives
and the various content areas being addressed in the web-based
survey and interview guide. The textual data from the survey and
interviews were coded by trained qualitative coders, using
ATLAS.ti to group and organize the coded content.
As the coding process continued, the coding framework was
expanded through the inclusion of any added concepts expressed
in the qualitative data collection. Newly assigned codes and the
grouping of like codes were reviewed frequently by the lead coder
and the principal investigators. Revisions were identiﬁed and
implemented, as needed, and reviewed with the coding team.
Once coding was completed, summary tables reporting the
results of the coding process were constructed to assess the
predominance (frequency) of subject expressions of each concept
in the transcript dataset and also to show the number of
individual transcripts (subjects) contributing to each detailed
group of coded expressions. Data quality was evaluated through
the assessment of 1) inter-rater agreement in the coded data, and
2) evidence of content saturation within the qualitative dataset.
The inter-rater agreement assessment tested the consistency
with which coders assigned concept codes to the qualitative
dataset. Open-ended questionnaire responses and interview
transcript data from 15% (3 of 20) of the participants completing
both the online survey and the follow-up interview were ran-
domly selected for independent dual coding by two members of
the coding team. The dual-coded data were compared to evaluate
the differences in code assignment. Consistency of coding was
found to be high, as agreement in the identiﬁcation of concepts to
be coded ranged between 85% and 94%, and agreement was
observed between coders in the assignment of speciﬁc codes for
87% to 93% of those identiﬁed concepts.
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chronologically by date of completion. Codes reported for each
successive participant’s response were compared with codes
from all preceding participants’ response data to identify the
point at which no further novel codes (and thus presumably no
new concept-level information) had appeared. The study used
data collection and analysis techniques based on current best
practice recommendations for establishing content validity of
PRO instruments for medical product evaluation [13].Results
Study Participants
Figure 1 details the ﬂow of participants through study recruit-
ment and data collection. Among the 299 invited members of
PLM’s CLL community, 71 participants completed the web-based
survey, of whom 53 also agreed to participate in the telephone
follow-up. An additional 29 individuals began the survey but did
not complete the full questionnaire.
The planned sample size for analysis of questionnaire
responses was 50. Because all members of the PLM community
were invited to complete the survey and 71 ultimately completed
the questionnaire, only the ﬁrst 50 participants (by date of
completion) were included for qualitative coding and retained
in the analysis set.
Demographic and clinical characteristics of the subjects are
reported in Table 1. Among subjects who completed the ques-
tionnaire, 36% of respondents had received treatment for theirUS-Based Members of PLM CLL Commun
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Fig. 1 – Study ﬂCLL, whereas the remaining 64% were treatment-naïve patients
whose CLL was being managed with a “watch and wait”
approach.
The majority of patients (78.0%) reported experiencing at least
one symptom; and 14% of patients reported their symptoms
required them to be in bed for up to 50% of their waking day
(performance status 2). There were no noteworthy differences in
demographic characteristics between subjects who participated
and those who did not participate in the telephone portion of the
study; however, a higher proportion of subjects who opted into
the telephone follow-up had received treatment for their CLL.Symptom and Impact Concepts Identiﬁed in Survey Responses
As displayed in Table 2, 369 expressions of symptoms were coded
in the open-ended survey responses. These symptom expres-
sions were organized into 30 different concept groups (subdo-
mains). With 85 combined coded expressions across all
respondents, fatigue and tiredness were the most frequently
expressed symptom concepts. Fatigue represented 13.6% of all
coded expressions of symptoms, whereas tiredness represented
9.5% of symptom expressions. Fatigue and tiredness were each
expressed by 20 of the 50 (40%) study participants, with seven
patients expressing fatigue alone in their responses, seven
patients expressing tiredness alone, and 13 using both fatigue
and tiredness to describe their symptoms.
The next most frequently expressed symptom concepts were
night sweats (38% of respondents; 9.5% of expressions), swollen
lymph nodes (32% of respondents; 11.7% of expressions), and
frequent infections (28% or respondents, 8.7% of expressions).ity 
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Table 1 – Demographic and clinical characteristics of study participants.
Web survey alone
N ¼ 30 (100%)
Web survey þ
phone interview N
¼ 20 (100%)
Total respondents
N ¼ 50 (100%)
Age (years) – Mean (SD) 58.7 (6.7) 63.1 (6.3) 60.5 (6.9)
– Median 58.0 62.5 60.0
– Range 48–74 53–78 48–78
Gender – Male 14 (46.7%) 9 (45%) 23 (46%)
– Female 16 (53.3%) 11 (55%) 27 (54%)
Marital status –Married or living as married 22 (73.3%) 14 (70%) 36 (72%)
– Widowed 3 (10%) — 3 (6%)
– Separated 1 (3.3%) — 1 (2%)
– Divorced 4 (13.3%) 2 (10%) 6 (12%)
– Never married — 4 (20%) 4 (8%)
Highest level of education
completed
– Less than high school — — —
– High school 2 (6.7%) 2 (10%) 4 (8%)
– Some college 18 (60%) 8 (52%) 26 (52%)
– Bachelor’s degree 6 (30%) 12 (12%)
– Graduate/ Professional
school
10 (33.3%) 4 (20%) 14 (28%)
Current employment status – Employed for wages 15 (50%) 4 (20%) 19 (38%)
– Self-employed 3 (10%) 2 (10%) 5 (10%)
– Unemployed 4 (13.3%) 2 (10%) 6 (12%)
– Homemaker – 1 (5%) 1 (2%)
– Retired (26.7%) (55%) (38%)
Health Insurance Status: – Employer-based 18 (60.0%) 8 (40%) 26 (52%)
– Private 4 (13.3%) 2 (10%) 6 (12%)
– Medicare 5 (16.7%) 6 (30%) 11 (22%)
– Medicaid 2 (6.7%) — 2 (4%)
– VA — 2 (10%) 2 (4%)
– Other type of insurance — 1 (5%) 1 (2%)
– Uninsured 1 (3.3%) 1 (5%) 2 (4%)
Hispanic, Latino, or Spanish
origin
– Yes — 1 (5%) 1 (2%)
– No 30 (100%) 19 (95%) 49 (98%)
Racial and ethnic group – American Indian/
Alaska Native
— — —
– Asian — — —
– Black or African American 2 (6.7%) — 2 (4%)
– Native Hawaiian or Other
Paciﬁc Islander
— — —
– White 28 (93.3%) 20 (100%) 48 (96%)
Self-reported current CLL
stage
– Never told 6 (20.0%) 6 (30.0%) 12 (24.0%)
– Don’t remember — 1 (5%) 1 (2%)
– Low risk (Rai 0 or
Binet A)
13 (43.3%) 7 (35%) 20 (40%)
– Intermediate risk (Rai 1
or 2 or Binet B)
8 (26.7%) 2 (10%) 10 (20%)
– High risk (Rai 3 or 4 or
Binet C)
3 (10%) 4 (20%) 7 (14%)
Self-reported performance
status
– Normal activity / No
symptoms (0)
13 (43.3%) 4 (20%) 17 (34%)
– Some symptoms, no bed
rest (1)
14 (46.7%) 12 (60%) 26 (52%)
3 (10%) 4 (20%) 7 (14%)
continued on next page
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Table 1 – continued
Web survey alone
N ¼ 30 (100%)
Web survey þ
phone interview N
¼ 20 (100%)
Total respondents
N ¼ 50 (100%)
– Require bed rest o50%
of day (2)
– Require bed rest 450%
of day (3)
— — —
Self-reported experience
with CLL symptoms*
– No 11 (36.7%) — 11 (22%)
– Yes 19 (63.3%) 20 (100%) 39 (78%)
Treatment group – Watch and wait /
treatment naïve
23 (76.7%) 9 (45%) 32 (64%)
○ Treatment naïve 22 9 31
○ Don’t intend to receive
treatment
1 — 1
– Treated 7 (23.3%) 11 (55%) 18 (36%)
○ Currently in ﬁrst line 2 5 7
○ Currently in second line 1 2 3
○ Currently in remission 4 4 8
CLL, chronic lymphocytic leukemia.
* Source of symptom grouping was response to self-reported survey item: “Have you ever experienced symptoms related to your CLL?”
V A L U E I N H E A L T H 1 9 ( 2 0 1 6 ) 4 2 – 5 2 47In addition to the items relating to symptoms of CLL, a
series of items in the questionnaire also addressed activity
limitations and other areas of life most affected by CLL.
As shown Table 2, impacts related to “worry, concern, and
fear” were the most frequently noted concepts across all
patients, experienced by 66% of respondents and representing
14.8% of all coded impact expressions. Other predominant
impact concepts included feelings of depression (52% of
respondents, 8.8% of expressions) and work limitations
(50% of respondents; 8.8% of expressions).
In evaluating saturation of concept, 36 of the 64 (56%)
concepts were identiﬁed in the ﬁrst 10 completed surveys; ﬁve
concepts were expressed for the ﬁrst time in the ﬁnal 10 tran-
scripts. The ﬁnal novel concept was coded in the 45th transcript
of the 50 assessed.
Concepts Identiﬁed During Telephone Interviews
Among respondents completing the web-based questionnaire,
71% consented to be contacted for follow-up. Thirty-two of those
participants had reported experiencing symptoms (and were thus
eligible to complete a telephone interview), the ﬁrst 20 of whom
completed an interview. Transcripts from the 20 telephone inter-
views were coded for symptom and impact concepts by using the
same initial coding framework that was used for analysis of the
online questionnaire responses.
This qualitative analysis indicated that there were four
symptom concepts (allergy/rash, bruising, cognitive difﬁculties,
and swelling in feet/ankles) and ﬁve impact concepts (irritability,
shock, difﬁculty staying asleep, use of medical additives, and
management of priorities) expressed by patients in the inter-
views that were not noted by those same patients in their online
questionnaire responses.
Comparison of Survey Findings to Concept Coverage of
Existing CLL Instruments
The set of symptom and impact concepts elicited through
patients’ responses to the web survey appeared to mirror quite
closely those included in prior CLL-speciﬁc PRO instruments.Speciﬁcally, across the 50 coded surveys, each of the symptom
concepts assessed by items of the FACT-Leu appeared as coded
expressions in the qualitative dataset. Similarly, each of the
general concept areas of the FACT-Leu’s Impact/QOL items
were identiﬁed in the survey responses (Table 3). Similarly,
each of the symptom and impact concepts assessed by the
items of the EORTC CLL-16 was expressed by survey respond-
ents in the current study except for dry mouth. Concepts such
as fatigue, feeling ill or unwell, difﬁculty doing daily activities,
worry about health in the future, and infections from the
CLL-16 were mentioned by the majority of survey respondents,
whereas bruising, weight loss, abdominal discomfort, body
temperature change, and skin problems were noted less
frequently.
Participant’s Attitudes toward Access to Clinical Data
Survey respondents indicated a high level of willingness to
provide researchers with access to their clinical information.
Over one-third of patients indicated that they would “very likely”
be willing through either of the two approaches described,
whereas less than 5% indicated they would be “not likely at all”
to provide access to the information (Table 4).
Between the two hypothetical approaches presented,
respondents indicated higher support for an approach in which
they collected information from their doctors and then provided
it to the researchers (mean rating of 7.4) than for an approach in
which permission was given for researchers to contact the doctor
directly (mean rating of 6.7).Discussion
This proof-of-concept case study assessed the feasibility of a
novel patient-powered, research network–based approach to
qualitative CE data collection. Survey results identiﬁed key con-
stitutional symptoms of CLL such as fatigue, tiredness, night
sweats, and lymph node swelling [20,21]. These symptoms
reported by study participants are well recognized B-cell symp-
toms that are also included in other disease-speciﬁc PRO
Table 2 – Summary of chronic lymphocytic leukemia (CLL) symptom and impact concepts coded in web-based
survey responses.
CLL Symptoms
subdomains and concepts
Number of coded
expressions of
concept
% of total coded
symptom expressions
(N ¼ 369)
Number of
patients
expressing
concept
% of patients
expressing concept
(N ¼ 50)
Low Energy and Fatigue 123 68%
Exhaustion 9 2.4% 7 14%
Fatigue 50 13.6% 20 40%
General tiredness 35 9.5% 20 40%
Low energy 16 4.3% 8 16%
Physical tiredness 6 1.6% 5 10%
Weakness 7 1.9% 5 10%
Pain and Discomfort 38 10%
Pain and discomfort 38 10.3% 12 24%
Impaired Immune
Functioning
155 42%
Anemia 2 0.5% 2 4%
General compromised
immune function
4 1.1% 3 6%
Fever 3 0.8% 3 6%
Infection 32 8.7% 14 28%
Lymph node swelling 43 11.7% 16 32%
Enlarged spleen 5 1.4% 3 6%
Night sweats 35 9.5% 19 38%
Feeling sick 12 3.3% 6 12%
Excessive sweating 7 1.9% 4 8%
White blood count
changes
11 3.0% 8 16%
Other immune-related
symptoms
1 0.3% 1 2%
Gastrointestinal (GI)
Symptoms
16 4%
Appetite changes 6 1.6% 6 12%
Nausea 4 1.1% 3 6%
Weight loss 3 0.8% 2 4%
Other GI-related
symptoms
3 0.8% 3 6.0%
Additional Symptoms 37 10%
Bleeding 4 1.1% 3 6%
Breathing difﬁculties 12 3.3% 6 12%
Bruising 1 0.3% 1 2%
Cognitive difﬁculties 2 0.5% 2 4%
Dizziness 6 1.6% 4 8%
Headache 3 0.8% 2 4%
Swelling in feet/ankles 4 1.1% 1 2%
Other symptoms 5 1.4% 3 6%
CLL impact subdomains and
concepts
Number of coded
expressions of
concept
% of total coded impact
expressions
(N ¼ 466)
Number of patients
expressing concept
% of patients
expressing concept
(N ¼ 50)
Physical Activity Limitations
and Restrictions
37 8%
Body movement 3 0.6% 1 2%
Restricted exercise 16 3.4% 9 18%
General physical activity
limitation
9 1.9% 7 14%
Limitation with stairs 1 0.2% 1 2%
Restricted walking 8 1.7% 7 14%
Difﬁculty with Daily
Activities
101 22%
Difﬁculty doing errands 2 0.4% 2 4%
General difﬁculty with
daily activities
26 5.6% 15 30%
continued on next page
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Table 2 – continued
CLL Symptoms
subdomains and concepts
Number of coded
expressions of
concept
% of total coded
symptom expressions
(N ¼ 369)
Number of
patients
expressing
concept
% of patients
expressing concept
(N ¼ 50)
Difﬁculty carrying out
household
responsibilities
30 6.4% 17 34%
Difﬁculty performing
personal care
activities
2 0.4% 2 4%
Difﬁculty with work
responsibilities
41 8.8% 25 50%
Social and Lifestyle
Limitations and
Restrictions
77 17%
Difﬁculty with leisure
activities
14 3.0% 10 20%
Relationship difﬁculties 24 5.2% 19 38%
Difﬁculty with sexual
activity
3 0.6% 3 6%
Difﬁculty with social
activities
32 6.9% 21 42%
Travel restrictions 4 0.9% 3 6%
Emotional Impacts 156 33%
Anger 8 1.7% 6 12%
Anxiety 17 3.6% 11 22%
Body image, self-esteem,
and embarrassment
8 1.7% 3 6%
Depression 41 8.8% 26 52%
Frustration 8 1.7% 7 14%
Irritability 5 1.1% 4 8%
Worry, concern, and fear 69 14.8% 33 66%
Other emotional impacts 0 0% 0 0%
Sleep Impacts 37 8%
Difﬁculty falling asleep 15 3.2% 8 16%
Difﬁculty staying asleep 1 0.2% 1 2%
Change in the quantity of
sleep
10 2.1% 6 12%
Change in the quality of
sleep
11 2.4% 8 16%
Aspects of Burden 3 1%
Financial difﬁculty 2 0.4% 2 4%
Needing assistance from
others
1 0.2% 1 2%
Coping Behaviors 55 12%
Denial 3 0.6% 2 4%
Self-education 8 1.7% 8 16%
Increased caution about
germs/sickness
6 1.3% 4 8%
Increased healthy habits 8 1.7% 7 14%
Medical additives 1 0.2% 1 2%
Altered outlook 11 2.4% 8 16%
Priorities and schedule
management
3 0.6% 3 6%
Increased rest 3 0.6% 3 6%
Social support 8 1.7% 5 10%
Other coping behaviors 4 0.9% 4 8%
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mouth) assessed by the CLL-16 [24] instrument was not expressed
by patients in our study.
When considering those 20 patients who completed both
the online survey and the qualitative interview, it is not-able that several symptom concepts (allergy/rash, bruising,
cognitive difﬁculties, and swelling in feet/ankles) and ﬁve
impact concepts (irritability, shock, difﬁculty staying asleep,
use of medical additives, and management of priorities) were
expressed by patients in the telephone interviews but not
Table 3 – Chronic lymphocytic leukemia (CLL) concept coverage in existing instruments and web-based survey
responses.
CLL concept
assessed
Concept coded in survey response data
and percent of responses in which
concept appeared
Fact-LEU subscale (17 items) item(s)
assessing concept
CLL-16 item(s)
assessing concept
Pain or
discomfort
Pain or discomfort: 24%  I have certain parts of my body where I
experience pain.
 Abdominal
discomfort
Lymph node
swelling
Lymph node  I am bothered by lumps or swelling in
certain parts of my body (e.g., neck,
armpits, or groin).
swelling: 32%
Night sweats Night sweats: 38%  I have night sweats.
 I am bothered by chills.
 Night sweats
Fevers Fever: 6%  I am bothered by fevers (episodes of high
body temperature).
 Temperature change
Bleeding and
bruising
Bleeding: 6%  I bruise easily.
 I bleed easily.
 Bruising
Bruising: 2%
Fatigue Fatigue: 40%  I feel weak all over.
 I get tired easily.
 Feel lethargic
 Feel slowed downTiredness: 40%
Weight loss Weight loss: 4%  I am losing weight.  Lost weight
activities Daily activities: 30%  I am able to do my usual activities.  Limited planning
activitiesLeisure activities: 20%
Social activities: 42%
Infections Infection: 28%  I worry about getting infections.  Chest infections
 Other infections
 Repeated
antibiotic use
Increased concern/caution about germs/
infection: 8%
Worry about
future health
and symptoms
Worry, concern, fear: 66%  I feel uncertain about my future health.
 I worry that I might get new symptoms
of my illness.
 Worry about
future health
 Worry about
infections
Altered outlook: 16%
Emotional
swings
Depression: 52%  I have emotional ups and downs.
Anxiety: 22%
Social isolation* Relationship difﬁculty: 38%  I feel isolated from others because of my
illness or treatment.Social activities: 42%
Appetite Appetite changes: 12%  I have a good appetite.
Dry mouth Concept not expressed in survey responses.  Had a dry mouth
Ill Feeling Sick: 12%  I feel ill.†  Feel ill or unwell
Skin problems Sores: 2%  Have skin problems
* Although patients described difﬁculty with relationships and limitations to their social activities, the term “isolation/isolated” was not
directly referenced in the coded survey responses.
† Although not part of the 17-item CLL-speciﬁc module, “I feel ill” is included as an item of the core FACT-G instrument.
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by inclusion of the telephone interview was the totality of
concepts identiﬁed on other instruments captured in this
subgroup of patients.
These ﬁndings suggest that qualitative data obtained through
digital communities and supplemented by telephone interview
can be potentially useful in supporting concept identiﬁcation for
newly developed PRO instruments.
The study highlights both the advantages and the challenges
of using this type of approach within the context of current
standards for evidence of content validity in PRO measurement,
including those required by the U.S. Food and Drug Administra-
tion Guideline to support label claims [28]. As one advantage, the
study process illustrates the beneﬁt of conducting patient
research with already-engaged members of digital communities.
Among the 147 invitees known to have received and opened their
survey invitation message, 68% began answering the survey
and 71% of those individuals completed their survey. Similarly,
participants appeared to show evidence of willingness to partic-
ipate in additional approaches to supplement self-reported data
with clinical information from their physicians, which bodes well
for future efforts of this kind.Other strengths of the study include the use of commonly
accepted [13] qualitative CE data coding and analysis methods,
formal assessment of concept saturation, and additional tele-
phone interviews to collect supplemental qualitative information
from a subset of respondents to further characterize the depth of
data gathered.
Considering results of symptomatic patients, the study gen-
erally identiﬁed expected disease symptoms (i.e., fatigue, infec-
tion, night sweats, and lymph node swelling). However, it is
notable that the contents of the FACT-Leu and CLL-16, both
developed using standardized methodology, lack 100% concord-
ance [23,24]. A more rigorous design would have been to
randomize subjects to an online survey versus traditional one-
on-one qualitative interview techniques (considered the gold
standard) to examine the degree to which online survey techni-
ques can replicate well-accepted methods of qualitative
research.
Despite these strengths of our approach, the study is poten-
tially limited by several key features. First, the self-reported
nature of clinical information limits the ability to describe the
speciﬁc characteristics of the study sample. For example, 26% of
respondents were unable to report the current stage of their CLL,
Table 4 – Participant attitudes regarding access to clinical information.
Description of approach presented Survey respondents
N ¼ 50 (100%)
OPTION 1 – Mean (SD) 6.7 (3.4)
Suppose you received a survey invitation from PatientsLikeMe (PLM) in the coming months that
asked you to allow the research team to contact your doctor for speciﬁc information about your
CLL.
– Median 8.0
– Range 0–10
– 0 – Not likely at all 2 (4%)
– 1 4 (8%)
– 2 3 (6%)
This information coming from your medical records is required by law to be treated as totally
conﬁdential. If you were to give permission for it to be used in research, it cannot be used in a
way that would allow anyone outside the research team to identify you personally.
– 3 2 (4%)
– 4 3 (6%)
– 5 4 (8%)
– 6 2 (4%)
– 7 4 (8%)
– 8 6 (12%)
– 9 2 (4%)
– 10 – Very likely 18 (36%)
Knowing this, how likely would you be to agree to this and provide your doctor’s contact
information?
OPTION 2 – Mean (SD) 6.7 (3.4)
We would like you to think about another option to gain the needed information without
researchers directly contacting your doctor. With this option, patients themselves would be asked
to obtain the speciﬁc medical information from their doctors and provide it to the study team.
– Median 8.0
– Range 0–10
– 0 – Not likely at all 1 (2%)
– 1 2 (4%)
– 2 1 (2%)
– 3 3 (6%)
Suppose you received a survey invitation from PLM in the coming months that asked you to
obtain speciﬁc medical information about your CLL from your doctor and then provide it to the
research team.
– 4 2 (4%)
– 5 4 (8%)
– 6 5 (10%)
– 7 2 (4%)
– 8 6 (12%)
How likely would you be to agree to this and obtain the information to provide? – 9 3 (6%)
– 10 – Very likely 21 (42%)
V A L U E I N H E A L T H 1 9 ( 2 0 1 6 ) 4 2 – 5 2 51and the accuracy of such self-reported information against
clinically conﬁrmed staging is unknown.
Second, the participant selection bias inherent in nonprob-
ability convenience samples such as ours may result in a study
sample that differs from the broader population of patients with
CLL. In particular, the survey respondents tended to be younger
and had a higher proportion of females than have been seen in
other CLL studies [29]. Additionally, we did not anticipate that
patients who were symptomatic and/or on active treatment
would be more willing to participate in the telephone portion of
the study. Such patients may be most interested in the manage-
ment of their condition or more willing to engage in research
activities to learn about their disease.
Third, although the lack of newly appearing concepts in the
ﬁnal ﬁve coded questionnaires suggests that no further relevant
information was likely to be elicited through additional partic-
ipants, this evidence of concept saturation in the online ques-
tionnaire data is not as strong as is often seen in qualitative CE
efforts. Particularly, the appearance of ﬁve newly coded concepts
within the ﬁnal 20% of the survey responses raises the possibility
that the elicitation of concepts through the web survey may not
have been fully exhaustive. Although many core symptoms were
identiﬁed, it is possible that other commonly experienced symp-
toms or impacts may not have been captured by the study
sample. It is also noteworthy that bruising, a symptom concept
assessed by both the CLL-16 and FACT-Leu instruments, was notexpressed in online questionnaire responses prior to the 43rd of
50 respondents.
When contrasted with in-person CE interview methods, which
often reach saturation between 15 and 25 participants, this ﬁnding
may suggest a need for larger sample sizes when using online
questionnaire-based approaches for concept elicitation. As such,
researchers need to consider closely the potential trade-offs in cost
and efﬁciency between online approaches, which may have lower
marginal data collection costs per enrolled patient but could require
larger sample sizes to be fully exhaustive, and traditional qualita-
tive interview methods, which may carry increased marginal data
collection cost per patient but may achieve concept saturation with
lower sample sizes. Although our focus in CLL provides an impor-
tant test of the methods within a relatively rare condition, it may be
helpful to test similar online qualitative data collection approaches
in more prevalent diseases, where the methods could more easily
be evaluated among larger samples of patients.
Finally, although the study design did not permit direct
comparisons between a standard CE interview and a CE effort
conducted via a web survey, the identiﬁcation of a small number
of novel symptom and impact concepts during the telephone
interview suggests that there may be some concepts that are
more likely to be elicited using more traditional qualitative
interviewing approaches.
Our ﬁndings provide early evidence of the general feasibility
of concept identiﬁcation conducted through digital patient
V A L U E I N H E A L T H 1 9 ( 2 0 1 6 ) 4 2 – 5 252communities, but suggest that online approaches alone may not
be sufﬁcient to achieve efﬁcient and exhaustive concept elicita-
tion. Approaches combining online questionnaires with
telephone-based qualitative interviews should be evaluated fur-
ther, particularly to identify whether the results from this type of
qualitative data collection approach can support content validity
of PRO instruments used as labeling endpoints in the same way
as traditional qualitative research methods.Acknowledgment
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